Wednesday, 08 May 2024
Spring Bank Pharmaceuticals
07:22 | 9/2/18
Nelson Research
Spring Bank Pharmaceuticals, Inc. (:SBPH) has been in the news after the price of the stock hit $12.01 at the conclusion of the most recent close.
more»
10:39 | 6/2/18
The Ledger Gazette
Spring Bank Pharmaceuticals logo Morse Asset Management Inc raised its stake in Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) by 18.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC ...
more»
Take Note: Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) has hit some technical weakness in its momentum, and while it has not broken down all the way through support -- watch the key levels that we discuss below and further, watch the stochastics and ...
more»
Investors look at the Volatility 12m to determine if a company has a low volatility percentage or not over the course of a year. The Volatility 12m of Spring Bank Pharmaceuticals, Inc. (NasdaqCM:SBPH) is 58.548400. This is calculated by taking weekly ...
more»
06:48 | 29/11/17
Dispatch Tribunal
Chardan Capital decreased their price target on Spring Bank Pharmaceuticals from $34.00 to $30.00 and set a buy rating for the company in a report on Tuesday, August 1st. ValuEngine downgraded Spring Bank Pharmaceuticals from a hold rating to a sell ...
more»
04:11 | 26/11/17
The Ledger Gazette
Spring Bank Pharmaceuticals logo Shares of Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) have been given a consensus rating of “Buy” by the six analysts that are currently covering the firm, MarketBeat.
more»
13:22 | 24/11/17
The Ledger Gazette
Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) - Equities researchers at William Blair dropped their FY2017 EPS estimates for shares of Spring Bank Pharmaceuticals in a note issued to investors on Wednesday, Zacks Investment Research reports.
more»
10:56 | 16/11/17
Seeking Alpha
Spring Bank Pharmaceuticals (NASDAQ:SBPH) announces positive results from the second cohort of Part A in the Phase 2 ACHIEVE study evaluating lead candidate inarigivir as a potential backbone in a combo treatment for chronic hepatitis B virus (HBV ...
more»
10:33 | 16/11/17
GlobeNewswire
HOPKINTON, Mass., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH) today announced top-line results from the second cohort (50mg monotherapy) of Part A of the ongoing Phase 2 ACHIEVE trial.
more»
06:48 | 4/11/17
Week Herald
Spring Bank Pharmaceuticals logo Morse Asset Management Inc raised its stake in Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) by 94.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC).
more»
Code | Last | Change |
COMP | 10,321 | 328 | | 3.08% |
DJI | 29,635 | 404 | | 1.34% |
SP500 | 3,583 | 87 | | 2.37% |
DAX | 12,438 | 82 | | 0.67% |
FTSE | 7,488 | 5 | | 0.07% |
NI225 | 22,420 | 408 | | 1.86% |
TWI | 67.27 | 0.00 | | 0.00% |